Coverage-gated living condition brief

Short Bowel Syndrome peptide evidence brief

A cited Short Bowel Syndrome peptide evidence brief across 25 exact-label ClinicalTrials.gov records, 3 connected profiles, and 8 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

25 selected records.

Connected peptides

3 profiles.

Registry update years

2016–2026 in selected records.

Direct collection answer · published August 17, 2026

What peptide evidence does PeptideScanner carry for Short Bowel Syndrome?

PeptideScanner’s selected collection contains 25 retained ClinicalTrials.gov records carrying the exact condition label “Short Bowel Syndrome,” connected to 3 peptide profiles across 8 registry-update years.

That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Short Bowel Syndrome, and it is not a safety or efficacy assessment.

Indication intelligence

Selected evidence landscape

Trial phases3

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses3

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 25 selected PubMed records and 1 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Short Bowel Syndrome unless their own cited source says so.

Related profile context

Literature connected through these peptide profiles

All literature facets →

This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Short Bowel Syndrome.

Teduglutide · source record 2026-02-08

Real-life experience of teduglutide use in pediatric patients with short bowel syndrome in Argentina. A multicenter study.

PubMed lists PMID 41647102 in Intestinal Failure (New York, N.Y.) as Journal Article, with publication-date metadata of 2024-11-28 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Glepaglutide · source record 2026-09-02

Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial.

PubMed lists PMID 41816796 in Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug glepaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Teduglutide · source record 2026-01-27

Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP).

PubMed lists PMID 35654733 in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver as Journal Article, Review, Consensus Statement, with publication-date metadata of 2022-05-31 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Teduglutide · source record 2026-01-27

Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy.

PubMed lists PMID 36177820 in Revista espanola de enfermedades digestivas as Case Reports, Journal Article, with publication-date metadata of 2023-06 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Teduglutide · source record 2026-01-27

Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure.

PubMed lists PMID 37001195 in Clinical nutrition (Edinburgh, Scotland) as Journal Article, with publication-date metadata of 2023-03-18 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Teduglutide · source record 2026-01-27

Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring.

PubMed lists PMID 37270288 in The American journal of clinical nutrition as Journal Article, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT03690206

PeptideScanner retained ClinicalTrials.gov record NCT03690206 at 2026-11-16T01:46:56.290Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was glepaglutide.

PeptideScanner change date
November 16, 2026
Cited source date
July 17, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03905707

PeptideScanner retained ClinicalTrials.gov record NCT03905707 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.

PeptideScanner change date
November 16, 2026
Cited source date
September 8, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04627025

PeptideScanner retained ClinicalTrials.gov record NCT04627025 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was apraglutide.

PeptideScanner change date
November 16, 2026
Cited source date
November 27, 2024
Evidence lane
Clinical trials

Exact-record source chronology

Short Bowel Syndrome registry timeline

All trial facets →

Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.

2026

4 records

2025

5 records

2024

3 records

2023

1 record

2022

2 records

2021

8 records

2020

1 record

2016

1 record
What this brief cannot answer